Sterna Sitting Pretty As Inflammatory Pipeline Shows Promise
Executive Summary
In an interview with Scrip, Sterna Biologicals CEO Christian Pangratz says that the small German company has a number of options available to advance its Phase II projects in asthma, COPD, ulcerative colitis and atopic dermatitis.
You may also be interested in...
Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company
Vectura's CEO James Ward-Lilley and incoming CFO from Skyepharma, Andrew Derodra, sat down with Scrip and explained where they see the excitement, synchronization and R&D fusion for the larger company.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.